Caribou Biosciences, Inc.
CRBU Nasdaq
SEC CIK 1619856
Follow Caribou Biosciences
Weekly email: filings, results
Revenue, last quarter
$1.6M
−26.9% vs same quarter last year
Net income
−$26.6M
+3.4% vs same quarter last year
EPS, diluted
−$0.25
+16.7% vs same quarter last year
Operating cash flow
−$22.5M
+10.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $11.2M | −$148.1M |
| FY24 | $10M | −$149.1M |
| FY23 | $34.5M | −$102.1M |
| FY22 | $13.9M | −$99.4M |
| FY21 | $9.6M | −$66.9M |
| FY20 | $12.4M | −$34.3M |
| FY19 | $5.8M | −$23.4M |
| FY18 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −1329.4% | −1327.4% |
| FY24 | −1667.2% | −1491.9% |
| FY23 | −336.6% | −296.1% |
| FY22 | −768.2% | −717.8% |
| FY21 | −697.8% | −697.3% |
| FY20 | −292.2% | −277.6% |
| FY19 | −592.7% | −404.8% |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$112.4M |
| FY24 | −$143.1M |
| FY23 | −$104.9M |
| FY22 | −$97.4M |
| FY21 | −$34.6M |
| FY20 | −$33.5M |
| FY19 | −$32.9M |
| FY18 | - |
- Caribou Biosciences
- Healthcare median
Show the numbers
| Year | Caribou Biosciences | Healthcare median |
|---|---|---|
| FY25 | −1327.4% | −30.6% |
| FY24 | −1491.9% | −47% |
| FY23 | −296.1% | −58% |
| FY22 | −717.8% | −80.4% |
| FY21 | −697.3% | −71.8% |
| FY20 | −277.6% | −62.2% |
| FY19 | −404.8% | −46.2% |
| FY18 | - | −49.6% |